Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly - Replaye Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as much as $600 a year on the pill.

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
replaye.com/novo-nordisk...

#News #NovoNordisk #Wegovy #ObesityDrugs #Drugs #EliLilly

Big Food pours millions into rebrands as obesity drugs reshape US demand Global food and beverage companies from PepsiCo to Coca-Cola are focusing on shorter ingredient lists and smaller pack sizes in 2026 as more people take appetite-suppressing GLP-1 drugs for weight los...

"Global food and beverage companies from PepsiCo to Coca-Cola are focusing on shorter ingredient lists and smaller pack sizes in 2026 as more people take appetite-suppressing GLP-1 drugs for weight loss."

#foodandbeverage #obesitydrugs

Hims & Hers copies Novo Nordisk's new Wegovy pill Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version

Competition has already arrived for Novo Nordisk's #Wegovy pill, as #telehealth company Hims & Hers launches a compounded version. #GLP1 #ObesityDrugs #WeightLossMedication #HimsAndHers #HealthNews #pharma
pharmaphorum.com/news/hims-he...

Sun Pharmaceutical Industries, India’s largest drugmaker by revenue, received regulatory approval to manufacture and sell generic semaglutide in India, intensifying competition with Novo Nordisk’s Wegovy.

#SunPharma #Wegovy #Semaglutide #ObesityDrugs #Ozempic

Eli Lilly and Novo Nordisk Race for India’s Obesity Drug Boom - Eli Lilly and Novo Nordisk are locked in a high-stakes race to dominate India’s fast-growing obesity drug market before low-cost...

Eli Lilly and Novo Nordisk Race for India’s Obesity Drug Boom
wiobs.com/eli-lilly-an...
#ObesityDrugs #IndiaHealthcare #PharmaIndustry #WeightLoss #GLP1 #EliLilly #NovoNordisk

#trends today for 'super mario' 'health officials' & 'obesity drugs'

Click/Tap below:

www.newsmason.com?query=%22sup...

www.newsmason.com?query=%22hea...

www.newsmason.com?query=%22obe...

#supermario #healthofficials #obesitydrugs

#trends today for 'super mario' 'health officials' & 'obesity drugs'

Click/Tap below:

www.newsmason.com?query=%22sup...

www.newsmason.com?query=%22hea...

www.newsmason.com?query=%22obe...

#supermario #healthofficials #obesitydrugs

🏆 Pfizer just beat Novo Nordisk in a $10B showdown for Metsera, one of the fiercest pharma battles since the race for COVID vaccines. The deal gives Pfizer a new shot at dominating the booming obesity drug market.

🔗 t.ly/zDK0p
#Pfizer #NovoNordisk #Metsera #PharmaDeals #ObesityDrugs

#trends today for 'passport sex markers' 'obesity drugs' & 'pm modi'

Click/Tap below:

www.newsmason.com?query=%22pas...

www.newsmason.com?query=%22obe...

www.newsmason.com?query=%22pm%...

#passportsexmarkers #obesitydrugs #pmmodi

New CEO to slash 9,000 jobs at Novo Nordisk in restructure Novo Nordisk will cut 9,000 jobs across the company as it reallocates resources toward growth and innovation in the obesity and diabetes markets.

#NovoNordisk #restructure #MikeDoustdar #obesity #diabetes #chronicdiseases #restructuring #obesitydrugs #EliLilly #drugcompounders #greymarketproviders #staffcuts #Moderna #Bayer #MSD #Iovance #CSL #Lundbeck #MostFavouredNationsdrugpricingscheme #tariffs #patentexpirations
zurl.co/Imo5i

Consuming More Protein May Protect Patients Taking Anti-Obesity Drug From Muscle Loss | Newswise Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small st...

Consuming More Protein May Protect Patients Taking Anti-Obesity Drug From Muscle Loss
www.newswise.com/articles/con...
#obesity #obesitydrugs #antiobesitydrugs #endo2025 #endocrinesociety #harvardmedicalschool #muscleloss #protein

In surprise move Wegovy-maker Novo Nordisk ousts CEO amid sagging sales Days earlier, Novo Nordisk cut its sales and profit forecast for first time since the launch of Wegovy four years ago.

6/9
💊 Novo Nordisk warns of layoffs as Wegovy slows
Stock fell 30%
📰 www.aljazeera.com/economy/2025...
#Pharma #ObesityDrugs #NovoNordisk

Viking Therapeutics (VKTX) Could Be Ready to Run Again - FFR Trading VKTX is gaining attention as its obesity drug trials progress. Here's why Viking Therapeutics VKTX could be poised for another breakout.

🚨 Chart of the Day: Viking Therapeutics (VKTX)
VKTX could be gearing up for another breakout 📈

Get the full breakdown here 👇
🔗 zurl.co/DCAI7

#VKTX #BiotechStocks #ObesityDrugs #StockMarket

#trends today for 'nico hulkenberg' 'tesla investors' & 'obesity drugs'

Click/Tap below:

www.newsmason.com?query=%22nic...

www.newsmason.com?query=%22tes...

www.newsmason.com?query=%22obe...

#nicohulkenberg #teslainvestors #obesitydrugs

Obesity drugs show promise for treating a new ailment: migraine Liraglutide, a member of the family of blockbuster weight-loss drugs, reduces headaches by half in a small study.

Can weight-loss drugs treat migraines?

A small pilot study suggests that liraglutide, a GLP-1 drug, might halve migraine frequency in people with obesity. The results are preliminary, but experts say they’re promising.

I wrote about it for @nature.com:

#Migraine #ObesityDrugs #GLP-1

A cautious culture cost Novo Nordisk its lead in the obesity drug race, former employees say Novo Nordisk's cautious approach to a triple-agonist obesity drug in the late 2010s, shelved due to...

Novo Nordisk's cautious approach to a triple-agonist obesity drug in the late 2010s, shelved due to side effect concerns, allowed Eli Lilly to gain ground in the market. Lilly's competing drug is now in late-stage testing. #ObesityDrugs #News

Structure Therapeutics shares rise on Pfizer’s obesity drug exit PFE hereremove ads Latest comments Install Our AppScan QR code to install app Google Play App Store Blog Mobile Portfolio Widgets About Us Advertise Help & Support Authors Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #Stocks #Investing #MarketNews #Pfizer #ObesityDrugs

Trump Rejects Proposal for Medicare to Cover Wegovy and Other Obesity Drugs Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid.

www.nytimes.com/2025/04/04/h...

#Trump Rejects Biden Plan to Expand Medicare Coverage for #ObesityDrugs
Administration officials reversed a decision made during the #Biden presidency that would have given millions of people access to weight-loss drugs paid for #Medicare and #Medicaid.

Llamas Are Now Being Used in Search for New Obesity Drugs Hi, it’s Lisa in London, where I’ve been learning about llamas helping find potential obesity treatments for humans. But before we get to that...

My latest piece for Bloomberg’s Prognosis newsletter is about a biotech company turning to llama antibodies in the search for new obesity drugs.
#health #biotech #obesitydrugs #llamas #prognosisnewsletter
www.bloomberg.com/news/newslet...

GPhC tightens rules for online obesity drug prescriptions The General Pharmaceutical Council (GPhC), which oversees UK pharmacies, has introduced stricter rules for online pharmacies prescribing obesity drugs. The regulator said the changes aim to prevent in...

GPhC tightens rules for online obesity drug prescriptions
This was originally posted on EasternEye:
www.easterneye.biz/gphc-rules-o...
#GPHC #Strictly #PrescriptionDrugs #ObesityDrugs #UnitedKingdom #healthiswealth #HealthyHabits

It only took two decades, but @fda.gov has issued new “draft” guidance for developing #ObesityDrugs.
Good News: They SAY obesity is a chronic disease.
Bad News: The don’t act like it.
conscienhealth.org/2025/01/new-...

Hot Obesity Drug Market Will Keep Investors Gripped Next Year Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.

2024 has been a volatile year for investors in weight-loss drug developers. My latest article with Angel Adegbesan delves into what happened this year and what to watch in 2025. Via @bloomberg.com
#stocks #markets #investing #obesitydrugs #pharma
www.bloomberg.com/news/article...